Inactive Instrument
Antibe Therapeutics Inc. Share Price
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/24/04 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/24/24 | Antibe Announces Appointment of Receiver | BU |
| 22/24/22 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/24/19 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/24/17 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 08/03/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 08/03/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 08/03/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 1.15Cr | |
| +2.24% | +5.83% | +58.47% | +65.65% | 6.67TCr | |
| +4.66% | +8.90% | +14.57% | +85.41% | 5.69TCr | |
| -0.60% | +1.73% | +23.48% | +94.40% | 5.65TCr | |
| +2.80% | +15.91% | +27.20% | +120.91% | 4.65TCr | |
| +2.59% | +7.82% | +30.79% | +45.20% | 4.48TCr | |
| +3.35% | +5.28% | +215.80% | +889.51% | 4.16TCr | |
| -0.47% | +9.60% | +27.53% | +52.88% | 3.53TCr | |
| +3.80% | -1.00% | +95.20% | +66.79% | 3.33TCr | |
| +0.55% | +5.21% | -40.08% | +391.03% | 2.51TCr | |
| Average | +1.94% | +3.29% | +50.33% | +201.31% | 4.52TCr | |
| Weighted average by Cap. | +2.25% | +3.97% | +51.17% | +179.78% |
Employees
11
